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Introduction {#sec1}
============

Diabetes mellitus (DM) affects 30.3 million people in the United States, i.e., 9.4% of the population, according to the 2017 National Diabetes Statistics Report ([@bib5]). Type 2 diabetes (T2DM) accounts for 90%--95% of all diabetic cases ([@bib5]). Ischemic and non-ischemic cardiovascular disease have been recognized for decades as the leading cause of morbidity and mortality in older adult T2DM ([@bib21]). Atrial fibrillation (AF) is the most common life-threatening cardiac arrhythmia in aging populations, and AF increases significantly in older persons having hypertension and T2DM ([@bib8]). Yet the underlying mechanism for the known association between AF and adult T2DM remains obscure ([@bib23]).

Type 2 diabetes is not an autoimmune disease. Yet circulating IgG autoantibodies have been reported in patients with advanced T2DM in association with specific neurovascular complications ([@bib29], [@bib30], [@bib31]). For example, in our prior report, IgG autoantibodies purified from patients with T2DM suffering with macular edema and albuminuric nephropathy potently induced stress fiber formation and Rho kinase-mediated apoptosis in endothelial cells ([@bib30]). Clustering of microvascular diabetic complications, i.e., painful neuropathy, maculopathy, and nephropathy triopathy, was observed in adult patients with T2DM harboring highly potent endothelial inhibitory autoantibodies ([@bib32]). Triopathy diabetic IgG autoantibodies evoked significant intracellular calcium elevation in endothelial cells as well as in differentiated, neuronal-like rat pheochromocytoma PC12 cells. Since many of the same patients manifested non-ischemic cardiomyopathy such as clinically significant AF and/or left ventricular hypertrophy, the possibility was suggested that IgG autoantibodies may alter intracellular calcium signals in cardiomyocytes as well. Disturbance in calcium homeostasis has been implicated in the pathogenesis of AF and other cardiovascular diseases ([@bib6]); thus, these IgGs may be arrhythmogenic and play an important role in T2DM non-ischemic cardiomyopathy. The present study provides evidence that circulating IgG autoantibodies from patients with T2DM with AF stimulated arrhythmogenic intracellular calcium release and revealed their signaling pathway in cardiomyocytes.

Calcium signaling has been known to be involved in the development of AF. AF often progresses from an intermittent to persistent stage and finally into permanent AF, which lasts for more than a year and remains as chronic ([@bib7]). The primary arrhythmia mechanisms underlying AF can be characterized into two major types, the focal ectopic firing and the re-entrant activity, for both of which calcium has been reported to be involved. First of all, both AF animal models and human patient atrial samples show abnormal atrial calcium signaling in AF pathophysiology through contributing to the ectopic activity, conduction block, and calcium-induced subcellular alternans mediated by after depolarization ([@bib16]). Second, re-entry has been identified as the other predominant mechanism that initiates and maintains arrhythmias ([@bib16]). Re-entry requires both a vulnerable substrate and a trigger to act on the substrate and initiate AF ([@bib16]). This study seeks to examine the underlying mechanism of how circulating IgG autoantibodies could trigger arrhythmogenic calcium signals in atrial myocytes.

Results {#sec2}
=======

Purified IgG Autoantibodies from Patients with T2DM/AF Induced Intracellular Calcium Elevation in Human and Mouse Cardiomyocytes {#sec2.1}
--------------------------------------------------------------------------------------------------------------------------------

To test whether IgG autoantibodies purified from patients with T2DM with AF (T2DM/AF) ([Table 1](#tbl1){ref-type="table"}) could alter intracellular calcium homeostasis in cardiomyocytes, human induced pluripotent stem cells (iPSCs) were differentiated into cardiomyocytes ([@bib26]). These cells were loaded with fluorescent calcium indicator Fura-2-acetoxymethyl ester (Fura-2, AM) and intracellular calcium level (presented as F~350nm~/F~385nm~) was monitored using live cell imaging. As shown in [Figure 1](#fig1){ref-type="fig"}A, addition of purified IgG autoantibodies from patients with T2DM/AF could induce a rapid intracellular calcium elevation in these human iPSCs-derived cardiomyocytes. This was also seen in isolated adult mouse atrial cardiomyocytes as shown in [Figure S2](#mmc1){ref-type="supplementary-material"}. Similar effects were observed in HL-1, a cardiomyocyte cell line derived from adult mouse atrium ([Figure 1](#fig1){ref-type="fig"}B). HL-1 cells contained the spontaneous calcium oscillations, and addition of purified IgGs from patients with T2DM/AF increased intracellular calcium and altered the oscillations\' pattern ([Figure 1](#fig1){ref-type="fig"}B). Since HL-1 cells responded to these IgG autoantibodies similarly to human cardiomyocytes, this mouse cell line was used in the following studies.Table 1Baseline Clinical Characteristics in ParticipantsRisk FactorDiabetesp Valueˆ, ∗AF (N = 28)No AF (N = 22)Age (years)63.9 ± 8.165.0 ± 11.50.57HbA~1~c (%)8.0 ± 1.48.2 ± 1.80.39HTN (%)82770.73Insulin use (%)64350.045ME, AMD (%)29230.75Nephropathy (%)18141.00[^3][^4][^5]Figure 1Purified IgG Autoantibodies from a Subset of Patients with T2DM and AF Induced Ca^2+^ Elevation in Both Human iPSC-Differentiated and Mouse CardiomyocytesRatio of fluorescence of fura-2 at two excitation (F~350nm~/F~385nm~) was used to monitor changes in intracellular Ca^2+^ concentration.(A) Representative trace of intracellular Ca^2+^ in iPSC-differentiated cardiomyocytes. The inserted panel is phase contract image of human iPSC-differentiated cardiomyocytes. IgGs: ∼30 μg/mL, n = 8.(B) Representative trace of intracellular Ca^2+^ in HL-1 cells. The spontaneous Ca^2+^ oscillations could be observed in most of the cardiomyocytes. IgGs: ∼30 μg/mL, n = 12.See also Figure S2.

HL-1 Cells Responded to IgG Autoantibodies from T2DM/AF but Not Control Subjects {#sec2.2}
--------------------------------------------------------------------------------

To examine whether the intracellular calcium homeostasis disturbing-IgG autoantibodies are specific for patients with T2DM/AF, intracellular calcium levels in cultured HL-1 cells were compared using purified IgG autoantibodies from patients with T2DM with AF and patients with T2DM without non-ischemic cardiomyopathy, i.e., no AF or left ventricular hypertrophy (control subjects). Addition of 5 μg/mL of IgG autoantibodies purified from control subjects failed to stimulate significant intracellular calcium elevation in HL-1 cells, whereas IgG autoantibodies from patients with T2DM/AF at the same concentration could induce a rapid calcium elevation ([Figure 2](#fig2){ref-type="fig"}A). IgG autoantibodies purified from 24 of 28 patients with T2DM/AF had significant responses, whereas IgG autoantibodies from 21 of 22 of control subjects failed to do so. The mean level of intracellular calcium elevation (presented as ΔF~350nm~/F~385nm~) in the autoantibodies from T2DM/AF (0.38 ± 0.01) significantly exceeded the mean level (0.08 ± 0.05) in control subjects ([Figure 2](#fig2){ref-type="fig"}B. ∗p \< 0.01). Similar results were observed in HL-1 cells using increased concentration of IgGs (30 μg/mL) ([Figures 2](#fig2){ref-type="fig"}C and 2D).Figure 2Intracellular Ca^2+^ Response in HL-1 Cells Treated with IgG Autoantibodies from Patients with T2DM with or without AF(A) Representative trace of intracellular Ca^2+^. The cardiomyocytes presenting spontaneous Ca^2+^ oscillations were selected for experiments. IgGs (2--5 μg/mL) derived from different patients were added at the indicated points (arrows). Control, T2DM without AF; DM/AF, T2DM with AF.(B) Statistics of changes in intracellular Ca^2+^ stimulated by IgGs. ∗p \< 0.01. Data are represented as mean ± SEM.(C) Representative trace of intracellular Ca^2+^. IgGs (30 μg/mL) derived from different patients were added at the indicated points (arrows).(D) Statistics of changes in intracellular Ca^2+^ stimulated by IgGs. ∗∗∗∗p \< 0.0001. Data are represented as mean ± SEM.See also Figure S2.

Pharmacological Characterization of IgG Autoantibody-Induced Calcium Elevation in HL-1 Cells {#sec2.3}
--------------------------------------------------------------------------------------------

To understand the mechanism underlying the IgG autoantibody-induced intracellular calcium elevation, the calcium sources were examined first using various pharmacological inhibitors. Incubation of verapamil up to 20 μM, which is known to almost completely inhibit L-type calcium channel in HL-1 cells ([@bib27]), failed to block these IgG autoantibody-induced intracellular calcium elevation ([Figure 3](#fig3){ref-type="fig"}A). Mibefradil is an antagonist for both L-type and T-type calcium channels and has IC~50~ at 0.4 μM for external K^+^ induced-calcium influx in HL-1 cells. Up to 25 μM mibefradil failed to block the IgG autoantibody-induced intracellular calcium elevation ([Figure 3](#fig3){ref-type="fig"}B). BTP-2 has been shown to block store-operated calcium entry (SOCE)-mediated calcium influx in cardiomyocytes ([@bib20]). Again, BTP-2 at concentration of 5 μM failed to block the IgG autoantibody-induced intracellular calcium elevation in HL-1 cells ([Figure 3](#fig3){ref-type="fig"}C). Interestingly, 100 μM concentration of 2-aminoethoxydiphenyl borate (2-APB) completely blocked the IgG-induced intracellular calcium elevation ([Figure 3](#fig3){ref-type="fig"}D). Addition of 20 mM caffeine at the end of experiments could induce a rapid calcium elevation (second arrow) indicating the sarcoplasmic reticulum (SR) calcium stores were intact. The quantification of the IgG autoantibody-induced calcium elevation is shown in [Figure 3](#fig3){ref-type="fig"}E. These data suggested that the IgG autoantibody-induced intracellular calcium elevation is independent of calcium influx from L-type, T-type calcium channels or SOCE.Figure 3Pharmacological Characterization of IgG Autoantibody-Induced Ca^2+^ Elevation in HL-1 Cells(A--D) IgGs (2 μg/mL) derived from patients with DM/AF resulted in intracellular Ca^2+^ elevation in HL-1 cells treated with mibefradil (A 25 μM), verapamil (B 20 μM), and BTP-2 (C 5 μM) but not in cells treated with 2-APB (D 100 μM). Caffeine, 20 mM, was added at the end of experiments to test whether SR Ca^2+^ stores were intact. n ≥ 3.(E) Statistical data of IgGs-induced changes in intracellular Ca^2+^ in HL-1 cells. ∗∗p = 0.0014. ∗∗p \< 0.0001. Data are represented as mean ± SEM.

IgG Autoantibody-Induced Intracellular Calcium Elevation was through IP~3~ Receptor {#sec2.4}
-----------------------------------------------------------------------------------

Since 2-APB at 100 μM could block both SOCE and inositol triphosphate (IP~3~) receptor (IP~3~R) ([@bib4]), an IP~3~-mediated mechanism for IgG autoantibody-induced calcium elevation was tested using a more specific antagonist for IP~3~R, i.e., xestosphongin C ([@bib17]). Incubation of HL-1 cells with 10 μM xestospongin C nearly completely blocked the IgG autoantibody-induced intracellular calcium elevation ([Figures 4](#fig4){ref-type="fig"}B and 4C), which was unaffected in HL-1 cells treated with vehicle alone ([Figures 4](#fig4){ref-type="fig"}A and 4C). The peak of intracellular calcium elevation responding to 20 mM caffeine indicated the intact SR calcium stores in both groups. To further examine the possible involvement of IP~3~R in the IgG autoantibody-induced intracellular calcium elevation, the genes encoding IP~3~R type 1 or type 2 were knocked down using a short hairpin RNA (shRNA) probe targeting the common sequences on the mouse mRNAs for IP~3~R1 and IP~3~R2 ([@bib25]). The efficacy of knocking down IP~3~R1 and IP~3~R2 proteins has been confirmed previously ([@bib25]) and currently by qRT-PCR ([Figure S1](#mmc1){ref-type="supplementary-material"}). IgG autoantibodies from T2DM/AF failed to induce intracellular calcium elevation in HL-1 cells transfected with plasmids containing shRNA specifically targeting IP~3~R1&2 ([Figure 4](#fig4){ref-type="fig"}E), but they were still able to do so in cells transfected with control plasmids ([Figure 4](#fig4){ref-type="fig"}D). Statistically, the averaged intracellular calcium changes presented as ΔF~350nm~/F~385nm~ were 0.08 ± 0.02 in cells transfected with shRNA against IP~3~R1&2 compared with 0.23 ± 0.02 in control cells ([Figure 4](#fig4){ref-type="fig"}F. ∗∗p \< 0.001).Figure 4Inhibition or Knockdown of IP~3~R Diminished IgG Autoantibody-Induced Ca^2+^ Elevation in HL-1 Cells(A and B) IgGs purified from patients with DM/AF were applied at the concentration of 2 μg/mL. The intracellular Ca^2+^ was recorded in HL-1 cells pre-treated with vehicle (A control) or 10 μM xestospongin C (B Xest C). Caffeine, 20 mM, was added at the end of experiments to test whether SR Ca^2+^ stores were intact.(C) Statistical data of IgGs-induced changes in intracellular Ca^2+^ in HL-1 cells treated with vehicle or Xest C. ∗p \< 0.01. Data are represented as mean ± SEM.(D and E) Representative traces of intracellular Ca^2+^ in HL-1 cells transfected with plasmids containing shRNA-control (D control) or shRNA-α-IP~3~R(E α-IP~3~R).(F) Statistical data of IgGs-induced changes in intracellular Ca^2+^ in HL-1 cells transfected with control or α-IP~3~R plasmids. ∗∗p \< 0.001. Data are represented as mean ± SEM.See also Figure S1 and Table S1.

PLC and GPCRs Mediated IgG Autoantibody-Induced Calcium Elevation in HL-1 Cells {#sec2.5}
-------------------------------------------------------------------------------

To reveal the mechanism underlying IgG autoantibody-induced IP~3~R-mediated intracellular calcium elevation, the pharmacological compounds, i.e., U-73122 ([@bib11]) and SCH-202676 ([@bib12]), were used to block PLC and G protein-coupled receptor (GPCR), respectively. As shown in [Figures 5](#fig5){ref-type="fig"}A and 5B, treatment with both U-73122 (10 μM) and SCH-202676 (50 μM) could significantly reduce IgG autoantibody-induced intracellular calcium elevation. Statistical data were summarized in [Figure 5](#fig5){ref-type="fig"}C.Figure 5PLC and GPCR Are Involved in IgG Autoantibody-Induced Ca^2+^ Elevation in HL-1 CellsIgGs from patients with DM/AF were applied at the concentration of (30 μg/mL).(A) Representative trace of IgG-induced Ca^2+^ in HL-1 cells treated with 10 μM U-73122.(B) Representative trace of IgG-induced Ca^2+^ in HL-1 cells treated with 50 μM SCH-202676.(C) Statistical data. n ≥ 5, ∗∗p \< 0.001. Data are represented as mean ± SEM.

Discussion {#sec3}
==========

In this study, we showed that circulating IgG autoantibodies from patients with T2DM/AF were able to induce intracellular calcium elevation in both human iPSC-differentiated cardiomyocytes and mouse adult atrial cardiomyocytes ([Figure 1](#fig1){ref-type="fig"} and [Figure S2](#mmc1){ref-type="supplementary-material"}). Such effects were not observed in the IgG autoantibodies from a control group of age-matched T2DM without atrial fibrillation, or left ventricular hypertrophy ([Figure 2](#fig2){ref-type="fig"}). The IgG autoantibody-induced intracellular calcium elevation was insensitive to L-type or T-type calcium channel blockers or SOCE blocker but was sensitive to either xestospongin c or knocking down of IP~3~Rs, indicating that the IgG autoantibody-induced intracellular calcium elevation was not dependent on voltage-gated calcium channel or store-operated calcium channel, but rather dependent on IP~3~Rs pathway. Both PLC and GPCR blockers were able to diminish IgG autoantibody-induced intracellular elevation, indicating the involvement of PLC and GPCR in the IgG autoantibody-induced arrhythmogenic effects ([Figure 5](#fig5){ref-type="fig"}). This is the first report, to our knowledge, of circulating IgG autoantibodies with activity of stimulating intracellular calcium signals in diabetic patients with AF. Taken together, these results demonstrated that the IgG autoantibodies purified from older patients with T2DM with AF could target an unknown GPCR, triggering IP~3~R-dependent pathways. This discovery suggested that the circulating IgG autoantibodies might play an important role in AF ([Figure 6](#fig6){ref-type="fig"}).Figure 6Working Model for Arrhythmogenic Calcium Signaling Induced by Circulating IgG Autoantibodies in Patients with T2DM/AFPharmacological data suggest that intracellular calcium elevation is through the GPCR-PLC-IP~3~-IP~3~R pathway.

This study revealed that IgG autoantibodies from patients with T2DM could trigger intracellular calcium elevation in both human iPSC-differentiated cardiomyocytes and mouse atrial cardiomyocytes. The altered intracellular calcium signals could contribute to the onset or development of AF. The significant association between intracellular calcium release in atrial cardiomyocytes evoked by IgG autoantibodies in T2DM with, but not without, co-morbid AF ([Figure 2](#fig2){ref-type="fig"}B) suggests a possible role for the IgG autoantibodies in AF causation. However, the exact contribution of these circulating IgG autoantibodies to the development of AF at different stages requires further investigation.

IP~3~ receptor-dependent pathways have been reported to play an important role in hypertrophy and remodeling of cardiomyocytes. Many key factors known to induce arrhythmogenic calcium signals occur through IP~3~ receptor-dependent pathways and thus regulate atrial structural and electrical remodeling associated with AF, such as angiotensin II and endothelin-1 ([@bib3]). For example, endothelin increases the formation of IP~3~ leading to enhanced calcium signaling, thus contributing to the development of atrial arrhythmias, which can ultimately lead to sudden cardiac death ([@bib13]). Up-regulation of IP~3~R expression has been found in atrial tissues of patients with chronic AF ([@bib28]). The G-protein signaling regulator RGS4 has been reported to be the molecular substrate for predisposition of AF ([@bib18]). Mice with global RGS4 deletion show higher frequency of AF development, calcium spark under basal condition as well as upon endothelin treatment, and abnormal spontaneous calcium release events after field stimulation in the atrial cells isolated from them, compared with the control littermates. RGS4 inhibits the G~q/11~, which activates the PLCβ that generates IP~3~ ([@bib24]). The role of IP~3~ in calcium signaling and the development of AF has also been reported in rat atrial myocytes ([@bib14]). The 2-APB-induced IP~3~R inhibition at 2 μM specifically suppresses the endothelin and IP~3~-evoked increase of calcium signal amplitude and extra calcium transients, which are absent under control conditions in rat atrial myocytes. Furthermore, in an animal study using the IP~3~R2-deficient mice, arrhythmogenic effects are abolished in the atrial myocytes isolated from IP~3~R2-deficient mice compared with those in the cells isolated from the wild-type littermates ([@bib13]). This study revealed that IP~3~-IP~3~R pathways mediate intracellular calcium elevation triggered by IgG autoantibodies from patients with T2DM/AF. Data suggest that pharmacologic blockers targeting IP~3~R pathways could be new drugs to neutralize harmful effects of IgG autoantibodies in treatment or prevention of AF in patients with T2DM.

Emerging evidence has implicated the involvement of autoimmunity in the development of AF in many autoimmune diseases, together with other factors contributing to the pathogenesis of AF, ranging from electrical, structural, and neurohumoral to inflammatory processes ([@bib10]). Several autoantibodies that play roles in the pathogenesis of AF include autoantibodies against GPCR superfamily proteins such as myosin heavy chain (MHC), sodium-potassium pump (Na/K-ATPase), the muscarinic cholinergic type 2 (M2) receptors, and the β1-adrenergic receptor ([@bib15]). The implications of autoantibody as upstream indicators of paroxysmal AF was shown in patients with congestive heart failure (CHF) ([@bib1]). In this cohort study of 95 patients with CHF and 48 age-matched control patients with hypertension, circulating autoantibodies against Na/K-ATPase are suggested to be an independent risk factor for the occurrence of paroxysmal AF. Autoantibodies against M2 receptors may play roles in the development of AF in patients with dilated cardiomyopathy (DCM) ([@bib2]). M2 autoantibodies are also found in patients with idiopathic AF ([@bib2]). M2 autoantibodies are confirmed to be independent predictors of the presence of AF in the patients indicated by multivariable analysis ([@bib2]). Autoantibodies against β1 and M2 facilitate the development of AF in patients with Graves\' hyperthyroidism ([@bib22]). T2DM is not an autoimmune disease, yet accumulating evidence showed that circulating IgGs from patients with T2DM, especially patients at advanced diseases stage or aged, present autoimmunity ([@bib32], [@bib30]). In this study, blocking GPCR could eliminate IgG autoantibody-triggered arrhythmogenic calcium signals, suggesting that these IgGs could target GPCRs. However, the exact GPCR and whether other antigens are involved in these IgG autoantibody-mediated effects in patients with T2DM/AF warrant further study.

In summary, this report highlighted that circulating IgGs from patients with T2DM/AF could induce arrhythmogenic calcium signals in cardiomyocytes. The results reported here shed light upon a possible mechanism underlying the association between increased risk of AF and T2DM. The circulating IgGs may serve as a biomarker for identifying a subset of patients with T2DM with an increased risk for the development of AF. Further identification of the receptors or antigens involved in IgG autoantibody-mediated IP~3~R activation could result in sentinel biomarkers to assess the risk factors for AF and/or novel approaches for AF prevention in patients with T2DM.

Limitations of the Study {#sec3.1}
------------------------

Some limitations to this study must be acknowledged. First, this study is limited by *in vitro* evidence. Although we have used human iPSC-differentiated, immortalized mouse atrial cardiomyocytes and isolated adult mouse atrial myocytes to reveal the arrhythmogenic calcium signaling induced by circulating IgGs purified from patients with T2DM with AF, we do not know whether the same effects can be recapitulated *in vivo*. Second, we do not know whether the IgG-evoked calcium elevations contribute to the onset or development of AF. Third, our findings have shown that the T2DM/AF IgGs could target GPCR and trigger the IP~3~R-dependent pathway; however, the exact GPCR involved is currently unknown and remains to be further investigated.
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